Recipharm appoints new position of Vice President Quality Management
Recipharm, the leading contract development and manufacturing organisation, is pleased to announce that it has appointed Thomas Beck to the new senior role of Vice President Quality Management (VP QM) with effect from 1st April 2015. Thomas is currently Head of Quality Control and Assurance at Recipharm Stockholm, a position that he has held since 2010. He is also Chairman of the Quality Assurance section within the Swedish Academy of Pharmaceutical Science.
In this new role Thomas will drive and coordinate the quality strategy and policy across the Recipharm Group subsidiaries and assist the Group Management Team (GMT) in monitoring and evaluating the company’s quality efforts. He will also lead the company’s audit process and support the sales activity by providing a primary contact point for new customers’ regulatory and quality affairs departments.
Reporting to the EVP Chief Operation Officer (COO) this post, represents an expansion of the Group Management Team (GMT) in a move designed to help it meet the increased demands the Group is facing following the recent rapid growth.
Commenting on the new appointment, Thomas Eldered, CEO of Recipharm, remarked: “This new position will bolster and enhance the work of the Group Management Team, meeting head on the quality management challenges our industry faces. Thomas will take a pivotal role in ensuring that we deliver and practice the highest standards of quality right across the entire Recipharm Group. He personally brings strong quality management expertise and already has specific experience of operations at Recipharm and the high standards that we are committed to delivering for our customers. I very much look forward to his authoritative support and direction being brought to bear for the benefit of the Group as a whole.”
Thomas Eldered, CEO, email@example.com, telephone: +46 8 602 52 10
Kjell Johansson, EVP COO, firstname.lastname@example.org, + 46 739 622620
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,200 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 3.3 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52 00, Fax 46 8 81 87 03